Explaining the Release Mechanism of Ritonavir/PVPVA Amorphous Solid Dispersions.
amorphous phase separation
glass transition
liquid–liquid phase separation
phase behavior
release
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
08 Sep 2022
08 Sep 2022
Historique:
received:
19
07
2022
revised:
30
08
2022
accepted:
01
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
In amorphous solid dispersions (ASDs), an active pharmaceutical ingredient (API) is dissolved on a molecular level in a polymeric matrix. The API is expected to be released from the ASD upon dissolution in aqueous media. However, a series of earlier works observed a drastic collapse of the API release for ASDs with high drug loads (DLs) compared to those with low DLs. This work provides a thermodynamic analysis of the release mechanism of ASDs composed of ritonavir (RIT) and poly(vinylpyrrolidone-co-vinyl acetate) (PVPVA). The observed release behavior is, for the first time, explained based on the quantitative thermodynamic phase diagram predicted by PC-SAFT. Both liquid-liquid phase separation in the dissolution medium, as well as amorphous phase separation in the ASD, could be linked back to the same thermodynamic origin, whereas they had been understood as different phenomena so far in the literature. Furthermore, it is illustrated that upon release, independent of DL, both phenomena occur simultaneously for the investigated system. It could be shown that the non-congruent release of the drug and polymer is observed when amorphous phase separation within the ASD has taken place to some degree prior to dissolution. Nanodroplet formation in the dissolution medium could be explained as the liquid-liquid phase separation, as predicted by PC-SAFT.
Identifiants
pubmed: 36145652
pii: pharmaceutics14091904
doi: 10.3390/pharmaceutics14091904
pmc: PMC9505701
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AbbVie (Germany)
ID : N/A
Références
Mol Pharm. 2019 Feb 4;16(2):877-885
pubmed: 30609372
Mol Pharm. 2019 Nov 4;16(11):4751-4754
pubmed: 31553871
Eur J Pharm Biopharm. 2020 Sep;154:387-396
pubmed: 32717391
Mol Pharm. 2019 Dec 2;16(12):5054-5067
pubmed: 31689113
J Pharm Sci. 2010 Sep;99(9):3787-806
pubmed: 20623696
Eur J Pharm Sci. 2019 Aug 1;136:104955
pubmed: 31199980
Eur J Pharm Biopharm. 2021 Jan;158:132-142
pubmed: 33212185
Pharm Res. 2020 Mar 16;37(4):70
pubmed: 32185516
J Pharm Sci. 2004 Jan;93(1):124-31
pubmed: 14648642
J Pharm Sci. 2001 Jul;90(7):888-901
pubmed: 11458337
J Pharm Sci. 2009 Aug;98(8):2549-72
pubmed: 19373886
Eur J Pharm Sci. 2010 Apr 16;40(1):25-32
pubmed: 20172027
Mol Pharm. 2016 Jun 6;13(6):2059-69
pubmed: 27138900
Eur J Pharm Sci. 2021 Mar 1;158:105682
pubmed: 33347981
Pharm Res. 2001 Jun;18(6):859-66
pubmed: 11474792
Pharmaceutics. 2021 May 17;13(5):
pubmed: 34067666
J Control Release. 2019 Mar 28;298:68-82
pubmed: 30731151
Mol Pharm. 2017 Jan 3;14(1):157-171
pubmed: 28043133
Pharm Res. 2017 Dec;34(12):2842-2861
pubmed: 28956218
Eur J Pharm Biopharm. 2015 Aug;94:352-62
pubmed: 26117187
Pharm Res. 1994 Apr;11(4):471-7
pubmed: 8058600
Mol Pharm. 2019 Mar 4;16(3):1327-1339
pubmed: 30669846
J Pharm Biomed Anal. 2010 Nov 2;53(3):359-65
pubmed: 20447794
J Pharm Sci. 2019 Jan;108(1):50-57
pubmed: 30439459